6-Azaspiro[2.5]octan-6-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 6-Azaspiro[2.5]octan-6-amine
• 英文别名: 6-azaspiro[2.5]octan-6-amine
• 化学式: C₇H₁₄N₂
• 分子量: 126.2
• InChiKey: LMXWQGGBARYARO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS 6-AMINO-QUINOLINONE ET DÉRIVÉS EN TANT QU'INHIBITEURS DE BCL6
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018108704A1

  公开（公告）日：2018-06-21

  The present invention encompasses compounds of formula (I), wherein the groups R1 to R5, X, Y and W have the meanings given in the claims and specification, their use as inhibitors of BCL6, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

  本发明涵盖了式(I)的化合物，其中基团R1至R5、X、Y和W具有权利要求和说明中给定的含义，它们作为BCL6的抑制剂的用途，含有这种化合物的药物组合物以及它们作为药物的用途，特别是作为治疗和/或预防肿瘤疾病的药剂。
• [EN] PYRIDINE DERIVATIVES AS KIF18A INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINE EN TANT QU'INHIBITEURS DE KIF18A
  申请人：AMGEN INC

  公开号：WO2021026100A1

  公开（公告）日：2021-02-11

  Amide compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

  化合物的酰胺类似物（公式（I））：如本文所定义，并其合成中间体，能够调节KIF18A蛋白，从而影响细胞周期和细胞增殖的过程，以治疗癌症和癌症相关疾病。该发明还包括包括这些化合物的药物组合物，以及治疗与KIF18A活性相关的疾病状态的方法。
• HETEROCYCLIC SUBSTITUTED PYRIMIDINE COMPOUND
  申请人：Xuanzhu Pharma Co., Ltd.

  公开号：EP2735567A1

  公开（公告）日：2014-05-28

  The present invention pertains to the field of medical technology, and particularly relates to a heterocyclic substituted pyrimidine compound represented by General Formula (I) and its pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description, the present invention also relates to a preparation method of the compound, a pharmaceutical composition containing the compound, and a use of the compound and the pharmaceutical composition in preparation of a medicine for enhancing a cGMP signal transduction function or a medicine for treating or preventing sexual dysfunction and diseases with lower urinary tract symptoms.

  本发明涉及医药技术领域，尤其涉及一种由通式(I)代表的杂环取代的嘧啶化合物及其药学上可接受的盐，其中R1、R2、R3、R4和R5如描述中所定义，本发明还涉及该化合物的制备方法、本发明还涉及该化合物的制备方法、含有该化合物的药物组合物，以及该化合物和药物组合物在制备增强 cGMP 信号转导功能的药物或治疗或预防性功能障碍和下尿路症状疾病的药物中的用途。
• TRICYCLIC HETEROCYCLIC DERIVATIVE HAVING HIV REPLICATION-INHIBITING EFFECT
  申请人：Shionogi & Co., Ltd.

  公开号：EP3144311A1

  公开（公告）日：2017-03-22

  The present invention provides the following compound having anti-HIV activity of formula: wherein, A1 is C, CR1A or N; A2 is C, CR2A, or N; A3 is CR3A, CR3AR3B, N, NR3c O, S, SO, or SO2 ; A4 is CR4A, CR4AR4B, N, NR4C O, S, SO, or SO2; A5 is C, CR5A, or N; T1 ring is substituted or unsubstituted monocyclic carbocycle or substituted or unsubstituted monocyclic heterocycle; R1 is halogen, cyano, nitro or -X1-R11; R2 is substituted or unsubstituted alkyl and the like; n is 1 or 2; R3 is hydrogen, substituted or unsubstituted aromatic varbocyclyl; R4 is hydrogen or a carboxy protecting group; the other symbols are as specified in the description.

  本发明提供了以下具有抗艾滋病毒活性的式化合物： 其中，A1 是 C、CR1A 或 N； A2是C、CR2A或N A3 是 CR3A、CR3AR3B、N、NR3c O、S、SO 或 SO2 ； A4 是 CR4A、CR4AR4B、N、NR4C O、S、SO 或 SO2； A5 是 C、CR5A 或 N； T1 环是取代或未取代的单环碳环或取代或未取代的单环杂环； R1 是卤素、氰基、硝基或-X1-R11； R2 是取代或未取代的烷基等； n 是 1 或 2； R3 是氢、取代或未取代的芳香变环； R4 是氢或羧基保护基团； 其他符号如说明中所述。
• NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2953681B1

  公开（公告）日：2017-03-15